Skip to main content
BLCO logo

Bausch + Lomb Corporation (BLCO) Stock: Price, Forecast & Analyst Target

Bausch + Lomb Corporation (BLCO) — MoonshotScore 35/100 (Weak band), calculated Nov 22, 2026. Price $19.38 (-6.33%), as of the Nov 20, 2026 trading session; market cap $6.93B. Expected results Feb 17, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 13.51× (market value Nov 20, 2026; cash Sep 30, 2026) · expected results Feb 17, 2027

$19.38 −$1.31 (-6.33%) Market Cap $6.93B

Bausch + Lomb Corporation · BLCO · NYSE · Healthcare · Medical - Instruments & Supplies

Research dated 2026-09-13: Bausch and Lomb operates across the full spectrum of eye care, manufacturing everything from daily contact lenses and over-the-counter drops to specialized surgical equipment. The investment case rests on whether the business can expand its pharmaceutical and surgical divisions rapidly enough to service a massive debt load while still funding necessary clinical research.

Price as of Nov 20, 2026

Key Statistics

35 of 100

MoonshotScore v2 · Bausch + Lomb (BLCO)

Weak
Business Quality Solid (73)
Financial Safety Strained (20)
Valuation Fair (70)
Growth Durability Growing (73)
Momentum Surging (91)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Fair; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • Altman Z 1.03 · Piotroski F 5
  • ROE -1.7% · ROA -0.8% · current ratio 1.56 · earnings yield -1.5% · free-cash-flow yield 3.4%

Holding back: balance-sheet strain

Helping: business quality, an attractive price, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BLCO (53 recorded, newest six shown)
RecordedScoreBand
35Weak
35Weak
35Weak
35Weak
35Weak
35Weak

The score was 35 in the stored Nov 21, 2026 snapshot and remains 35 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Valuation +3 and Financial Safety +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$19.38
Change on the day-6.33%
52-week range$14.44–$21.40
Market capitalisation$6.93B
Shares traded on the day871.6K
Beta (volatility vs the S&P 500)0.52

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $15, high $21, latest $19. 4 reported quarters marked, 3 above and 1 below the recorded estimate. 1 other dated event marked. $21 $15 high $21 Feb 18, 2026 · Earnings results · reported below the recorded estimate · close $181Apr 29, 2026 · Earnings results · reported above the recorded estimate · close $162Jul 29, 2026 · Earnings results · reported above the recorded estimate · close $173Oct 28, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $204Oct 28, 2026 · Earnings results · reported above the recorded estimate · close $205 Oct 17, 2025 Nov 20, 2026 · $19 $15Oct 17, 2025$15Oct 31, 2025$16Nov 14, 2025$16Nov 28, 2025$17Dec 12, 2025$17Dec 26, 2025$17Jan 9, 2026$17Jan 23, 2026$17Feb 6, 2026$18Feb 20, 2026$17Mar 6, 2026$16Mar 20, 2026$16Apr 2, 2026$17Apr 17, 2026$16May 1, 2026$16May 15, 2026$16May 29, 2026$15Jun 12, 2026$16Jun 26, 2026$16Jul 10, 2026$16Jul 24, 2026$17Aug 7, 2026$17Aug 21, 2026$18Sep 4, 2026$17Sep 18, 2026$17Oct 2, 2026$16Oct 16, 2026$20Oct 30, 2026$21Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • We continue to expect interest expense of approximately $365 million and full year CapEx of approximately $285 million. We now expect the adjusted tax rate to be approximately 18%, slightly below our previous outlook of 19.0%.

    Osama A. Eldessouky · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

What to watch next

Other perspectives

Council score for Bausch + Lomb (BLCO): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Moderate
Growth Durability Moderate
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 22, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Weak
ROE Negative
Gross Margin Moderate

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Bausch + Lomb (BLCO), and what does it report?

Short answer · as of

While the industry classification groups the business with medical instruments suppliers, the enterprise actually operates distinct divisions under a unified corporate umbrella.

The consumer segment functions like a traditional packaged goods operation, generating revenue through recurring retail purchases of contact lenses and eye drops.

In contrast, the surgical and pharmaceutical arms act as specialized medical technology developers. These divisions require continuous research spending to engineer advanced intraocular lenses, surgical machinery, and proprietary prescription medications for complex ocular diseases.

2 · Latest results

What do the latest results show for Bausch + Lomb (BLCO)?

Recent financial reports show reliable revenue expansion, yet the bottom line remains mired in net losses. This persistent divergence stems from structural operating costs and debt obligations rather than any deficiency in consumer demand for eye care products.

Executives credit moderating currency exchange headwinds for preserving some top-line momentum. However, management also acknowledges that research and development spending must remain elevated as a share of total revenue to maintain a competitive product pipeline.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$1.38B Sep 30, 2026
Latest quarter · R&D
$91.00M Sep 30, 2026
Latest quarter · SG&A
$556.00M Sep 30, 2026
Latest quarter · FMP standardized operating result
$155.00M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$1.38B$91.00M$556.00M$155.00M
Jun 30, 2026$1.39B$114.00M$588.00M$83.00M
Mar 31, 2026$1.24B$101.00M$544.00M$59.00M
Dec 31, 2025$1.41B$94.00M$564.00M$158.00M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.38B Oct 28, 2026
Latest report · revenue estimate
$1.37B Oct 28, 2026
Latest report · revenue vs estimate
Above estimate Oct 28, 2026
Latest report · EPS vs estimate
Above estimate Oct 28, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 28, 2026$1.38B$1.37B$0.3400$0.2145
Jul 29, 2026$1.39B$1.37B$0.1600$0.1544
Apr 29, 2026$1.24B$1.22B$0.0800$0.0600
Feb 18, 2026$1.41B$1.39B$0.3200$0.3500
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$1.28B-$28M-$0.08 (diluted)
Q4 FY2025$1.41B-$58M-$0.16 (diluted)
Q1 FY2026$1.24B-$71M-$0.20 (diluted)
Q2 FY2026$1.39B-$14M-$0.04 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Bausch + Lomb (BLCO)?

Short answer · as of

Cash and short-term investments were $513.00M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $233.00M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

The balance sheet presents the most acute risk to equity holders. Total liabilities thoroughly dwarf the available cash and short-term investments, creating a highly leveraged capital structure that restrains strategic flexibility.

While cash flow from core operations remains positive and comfortably covers routine capital expenditures, the sheer scale of the corporate debt demands constant attention. This leverage leaves the enterprise vulnerable to elevated borrowing costs or any sudden contraction in consumer spending on premium health products.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.03 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-1.7%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$233.00M Sep 30, 2026
Previous quarter · operating cash flow
$153.00M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$233.00M−$55.00M
Jun 30, 2026$153.00M−$71.00M
Mar 31, 2026$32.00M−$100.00M
Dec 31, 2025$134.34M−$72.54M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Bausch + Lomb (BLCO)?

Short answer · as of

The next earnings report is expected on Feb 17, 2027.

The upcoming earnings disclosure will test whether the company can maintain its historically consistent pattern of surpassing consensus revenue estimates. Market observers will monitor operating margins closely to see if the promised stability in gross profitability actually materializes amidst fluctuating global currency dynamics.

Any unannounced reduction in research spending or capital expenditures would signal a shift toward urgent cash preservation. Conversely, sustained investment levels would confirm management confidence in the current liquidity position and the broader product pipeline.

What management is planning

Management's statement is quoted under Upcoming events

5 · Peer comparison

How does Bausch + Lomb compare with its peers?

Short answer

Bausch + Lomb's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Unlike pure pharmaceutical developers or narrowly focused surgical device makers, this enterprise bundles specialized medical technology with high-volume retail consumer goods. This structural integration creates a distinct revenue buffer.

Because the portfolio spans from basic saline solutions to complex surgical equipment, an unexpected setback in clinical drug trials or regulatory device approvals can be partially cushioned by steady, recurring sales of everyday contact lenses and over-the-counter allergy drops.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
TG Therapeutics, Inc. (TGTX) Named competitor$63.34 Nov 20, 2026$9.57B92 5-pillar Nov 22, 2026
Haemonetics Corporation (HAE) Same industry, near in market value$120.16 Nov 20, 2026$5.47B82 5-pillar Nov 22, 2026
Merit Medical Systems, Inc. (MMSI) Same industry, near in market value$84.34 Nov 20, 2026$5.05B82 5-pillar Nov 22, 2026
AptarGroup, Inc. (ATR) Same industry, near in market value$140.08 Nov 20, 2026$8.88B78 5-pillar Nov 22, 2026
ICU Medical, Inc. (ICUI) Same industry, near in market value$172.52 Nov 20, 2026$4.31B74 5-pillar Nov 22, 2026
Stevanato Group S.p.A. (STVN) Same industry, near in market value$15.65 Nov 20, 2026$4.27B74 5-pillar Nov 22, 2026
Avantor, Inc. (AVTR) Same industry, near in market value$14.84 Nov 20, 2026$10.1B71 5-pillar Nov 22, 2026
Repligen Corporation (RGEN) Same industry, near in market value$163.81 Nov 20, 2026$10.5B71 5-pillar Nov 22, 2026
Teleflex Incorporated (TFX) Same industry, near in market value$161.58 Nov 20, 2026$6.41B62 5-pillar Nov 22, 2026
Baxter International Inc. (BAX) Same industry, near in market value$25.39 Nov 20, 2026$13.1B58 5-pillar Nov 22, 2026
Vaxcyte, Inc. (PCVX) Named competitor$55.39 Nov 20, 2026$8.77B51 5-pillar Nov 22, 2026
The Cooper Companies, Inc. (COO) Same industry, near in market value$58.88 Nov 20, 2026$11.2B40 5-pillar Nov 22, 2026
Bausch + Lomb (BLCO) — this page$19.38$6.93B35

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$17.00 – $24.00
Consensus target
$21.75
Median target
$22.50

Consensus record · Captured .

Measured against a quoted price of $19.38 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 29, 2026

Transactions
32
Identified insiders
19
Purchases
0
Sales
4
Other transactions
28

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
10.4% Period end Sep 30, 2026
Previous quarter · ownership
10.7% Prior to period end Sep 30, 2026
Reporting holders
107 Period end Sep 30, 2026
Previous quarter · holders
102 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Brookfield Corp /On/4,565,719
D. E. Shaw & Co., INC.3,379,704
Deutsche Bank AG\3,329,257
Davidson Kempner Capital Management LP3,158,972
Goldentree Asset Management LP3,106,987

Tracked investors

Which of the 16 named investors we follow held BLCO in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Icahn CapitalCarl IcahnQ3 20260.43%$40.43MTrimmed −32.1% shares
Third PointDan LoebQ3 20260.03%$1.45MHeld, unchanged

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Bausch + Lomb (BLCO)?

Read these with our analysis →

Common Questions About BLCO (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

What drives revenue in the surgical segment?

The surgical division generates income by supplying the machinery and specialized tools required for complex procedures like cataract removals and retinal treatments. Growth here relies on medical facilities continually upgrading their phacoemulsification equipment and purchasing proprietary intraocular lenses for their patients.

How do currency fluctuations affect the business?

Because the company manufactures and distributes products globally, varying exchange rates can significantly alter reported revenue. Management recently noted that stabilizing foreign exchange conditions are providing a modest tailwind, slightly easing the pressure on overall profitability.

Why does the company report consistent net losses despite growing sales?

Strong consumer demand for eye care products drives healthy revenue, but the resulting gross profit is consumed by structural overhead, continuous research funding, and significant debt service obligations. Until operating margins expand or the debt burden shrinks, the enterprise will likely continue prioritizing operating cash flow over strict accounting profitability.

Does the consumer health division offer anything besides contact lenses?

The consumer portfolio extends well beyond basic corrective lenses to include comprehensive lens care solutions, over-the-counter diagnostic drops, and specialized nutritional supplements. These retail products target widespread, chronic conditions like ocular allergies and dry eye, creating a reliable stream of repeat purchases.

What is the BLCO stock price today?

The last price recorded for Bausch + Lomb Corporation (BLCO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BLCO price target?

The analyst consensus price target for Bausch + Lomb Corporation (BLCO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 81 figures on this page — 2 from SEC filings and earnings calls, 72 from Financial Modeling Prep (FMP), 2 with no recorded source, 3 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Cash, investments and debt; Revenue by segment; Annual revenue and net result (USD millions)
  • 1. What is Bausch + Lomb (BLCO), and what does it report?: Sector / industry (provider taxonomy); Revenue by segment; Business description; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Bausch + Lomb (BLCO)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Management outlook — dated call excerpts; Reported versus estimated, last 8 quarters
  • 3. What are the financial strengths and risks for Bausch + Lomb (BLCO)?: Cash, investments and debt; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • 4. What should you watch next at Bausch + Lomb (BLCO)?: Next earnings report; Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Analyst revenue and earnings estimates (average)
  • 5. How does Bausch + Lomb compare with its peers?: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • FAQ: What drives revenue in the surgical segment?: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • FAQ: How do currency fluctuations affect the business?: Management outlook — dated call excerpts; Revenue by segment; Business description
  • FAQ: Why does the company report consistent net losses despite growing sales?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Cash, investments and debt
  • FAQ: Does the consumer health division offer anything besides contact lenses?: Business description; Revenue by segment; Sector / industry (provider taxonomy)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.